Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over ...
In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
(RTTNews) - Rapport Therapeutics, Inc. (RAPP) said the U.S. FDA has cleared the company to advance RAP-219 into registrational trials, allowing accelerated initiation of its Phase 3 program in focal ...
Rapport Therapeutics, Inc. (NASDAQ:RAPP) stock traded higher on Monday, with a session volume of 3.20 million compared to the average volume of 179.3 thousand, according to data from Benzinga Pro. On ...
Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well tolerated Patients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% ...
Robust efficacy, competitive tolerability and ease of administration. Those are the qualities for a potential blockbuster antiseizure medication, according to Abe Ceesay, CEO of Rapport Therapeutics ...
BOSTON and SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Rapport Therapeutics, Inc. (Nasdaq: RAPP), please note the references to the ...
Shares of Rapport Therapeutics Inc. (NASDAQ:RAPP) were trading up more than 100% at midday on the back of a phase IIa readout showing RAP-219, its TARPĪ³8-specific AMPAR negative allosteric modulator, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results